Date:11/02/2022	
Your Name: Xiufei Gao	
Manuscript Title: GeneChip expression	profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known): ATI	Л-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name: Zimei Yang	
Manuscript Title: GeneChip expre	ssion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
_	in item #1 above).		
3	Royalties or licenses	XNone	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name:Chuchu Xu	
Manuscript Title: GeneChip expre	ssion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
	_	Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name:Qinghong Yu	
Manuscript Title: GeneChip express	ion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
_	in item #1 above).		
3	Royalties or licenses	XNone	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name:Mengqian Wang	
Manuscript Title: GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells	
Manuscript number (if known): ATM-22-757	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	minum of the week
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date: 11/02/2022	
Your Name:Jiaqing Song	
Manuscript Title: GeneChip expres	ssion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
	_	Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name:Chunyu WU	
Manuscript Title: GeneChip expre	ssion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement:

Date:11/02/2022	
Your Name:Mingcang Chen	
Manuscript Title: GeneChip expres	ssion profiling identified OLFML2A as a potential therapeutic target in TNBC cells
Manuscript number (if known):	ATM-22-757

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,	National Natural Science	82074438
	provision of study materials,	Foundation of China	
	medical writing, article	Natural Science	LY18H270006
	processing charges, etc.)	Foundation of Zhejiang	
	No time limit for this item.	Province	
		Zhejiang Province	2016ZQ015
		Traditional Chinese	
		Medicine Scientific	
		Research Foundation	
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	

	0 111 6	V	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Company for attending	V 1	
/	Support for attending meetings and/or travel	XNone	
	ğ ,		
8	Patents planned, issued or	XNone	
	pending		
_		•	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by The National Natural Science Foundation of China (No. 82074438), the Natural Science Foundation of Zhejiang Province (No. LY18H270006), and the Zhejiang Province Traditional Chinese Medicine Scientific Research Foundation (No. 2016ZQ015)

Please place an "X" next to the following statement to indicate your agreement: